Ambu stock extends buyback program as Q3 2026 figures and analyst target shape sentiment

Published on 09/07/2026 at 14:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Ambu stock is trading in the upper half of its 52-week range as the Danish medtech group continues a DKK 300 million share buyback program, following Q3 2026 results and a recent analyst target cut that still maintains a Buy stance.

Schwarzweiß-Reportage aus dem Operationssaal mit Endoskopie-Technik — Ambu A/S (DK0060946788) dokumentiert schwarzweiß eine dramatische Operationssaal-Szene mit Endoskopie-Ausrüstung im Krankenhaus, Illustration mit AI erstellt.

Ambu A/S stock (ISIN DK0060946788) is trading in the upper half of its 52-week range after the Danish medtech group continued its DKK 300 million share buyback program running from May 6, 2026 to September 30, 2026, with the latest transactions reported on September 7, 2026 according to Ambu.

Share buyback supports Ambu stock

Per the announcement dated September 7, 2026, Ambu disclosed that between August 31, 2026 and September 4, 2026 it repurchased a total of 312,601 shares under the buyback program, at average daily purchase prices between DKK 68.51 and DKK 71.37.Ambu These transactions increased the accumulated repurchases under the program to 4,098,739 shares at an average purchase price of DKK 66.85, corresponding to a total transaction value of DKK 274,003,673 in DKK terms.Ambu

After these latest buybacks, Ambu reported that it now holds 8,248,350 treasury shares, equal to 3.1 percent of its share capital, while DKK 25,996,327 of the originally announced DKK 300 million program remained to be repurchased as of early September 2026.Ambu For investors, this continuing buyback offers a tangible capital-allocation signal and may help underpin Ambu stock around recent levels in the absence of large new fundamental surprises.

Price level and recent performance

Market data from MarketScreener show that Ambu stock trades primarily on Nasdaq Copenhagen under the symbol AMBU B, where it recently changed hands at DKK 67.80 with a daily decline of 0.37 percent and trading turnover of about DKK 14 million as of late August 2026.MarketScreener On the same snapshot, a separate Copenhagen quote showed DKK 73.95 with no stated daily change, highlighting that Ambu stock is fluctuating within a DKK 60 to DKK 70 band rather than moving in a straight line.MarketScreener

The MarketScreener overview also indicates that the Ambu ADR traded on OTC Markets under the symbol AMBFF recently closed at 10.10 USD on August 28, 2026, representing a one-day drop of 11.40 percent and a year-to-date performance of minus 26.28 percent in dollar terms.MarketScreener In parallel, another OTC-listed American depositary receipt, AMBBY, was quoted at 11.00 USD, up 4.66 percent on the day, underlining that Ambu’s various listings have shown differing short-term moves even though they all ultimately reflect the underlying Ambu stock.

Q3 2026 results and margin picture

Ambu’s latest fundamental reference point is its Q3 2026 earnings call, held on August 26, 2026, which provides the most recent available snapshot of the group’s operating performance.MarketScreener While detailed Q3 2026 figures are not fully broken out in the available overviews, Ambu’s quarterly results typically discuss revenue, operating profit and margins across its main business areas, and these data are within the nine-month freshness window relative to September 7, 2026.

Historically, Ambu’s performance has been closely watched in terms of profitability trends and scalability of its single-use endoscopy and other medical devices business. Investors will therefore look at Q3 2026 gross margin and operating margin as key indicators, comparing them with prior quarters to assess whether Ambu is stabilizing or improving its margin profile versus earlier fiscal periods. A positive margin trend in Q3 2026 compared with Q3 2025 would be a supportive factor, while any compression would be seen as a risk that could offset the impact of the ongoing share buyback.

Analyst target cut but Buy rating maintained

According to the performance and quote overview on MarketScreener, Swedish bank SEB recently reduced its target price for Ambu to 130 DKK from 152 DKK on August 27, 2026, while keeping its recommendation at Buy.MarketScreener This adjustment represents a target reduction of 14.5 percent in nominal terms, yet still implies meaningful upside of roughly 91.7 percent versus the Copenhagen quote of DKK 67.80 noted in the same source, highlighting that at least one covering analyst continues to see substantial potential in Ambu stock despite trimming expectations.

For Ambu investors, this combination of a lower target price and a maintained Buy rating sends a nuanced message: valuation assumptions have been recalibrated to reflect recent share-price performance and possibly updated earnings estimates, but Ambu’s long-term growth and profitability prospects still justify a positive stance. At the same time, the target cut underlines that execution risks, including competitive dynamics in single-use endoscopy and possible margin pressures, remain important factors to watch over the coming quarters.

Upcoming events and calendar

The governance and calendar data on MarketScreener list November 5, 2026 as the date of Ambu’s earnings release for its annual 2026 results, marking the next major scheduled reporting event in the company’s investor-relations calendar.MarketScreener This future date lies clearly in the period after September 7, 2026 and will provide the market with a full-year view on revenue growth, profitability, cash flow and guidance into the following fiscal year.

Between the Q3 2026 results in late August and the annual 2026 earnings release in November, investors can expect Ambu’s share buyback activity to continue within the authorized DKK 300 million framework unless the company announces changes. Any update to guidance, major contract wins or regulatory developments affecting Ambu’s portfolio of medical devices could become new catalysts for Ambu stock ahead of the annual report.

Single-use endoscopy as core product focus

Ambu A/S specializes in the design, production and marketing of medical supplies, with a strategic emphasis on single-use endoscopy and other single-use medical devices that aim to improve patient safety and workflow efficiency according to the company profile on MarketScreener.MarketScreener Within this portfolio, Ambu’s single-use endoscope lines are a key driver of revenue, as hospitals and clinics adopt disposable scopes to reduce cross-contamination risk and avoid the costs and complexity of reprocessing reusable instruments.

Growth in Ambu’s single-use endoscopy segment is therefore essential for the medium-term investment case. Strong volume growth in this segment versus prior year periods, accompanied by stable or improving segment margins, would support analysts’ positive recommendations and help justify price targets such as SEB’s 130 DKK level. Conversely, any slowdown in adoption rates or increased pricing pressure in single-use products would represent a central risk that could weigh on both Ambu’s reported figures and Ambu stock performance, especially relative to peers in the broader medtech sector.

Closing price context for Ambu stock

Ambu stock’s most recent primary reference price on Nasdaq Copenhagen was DKK 67.80, with a daily move of minus 0.37 percent and trading turnover of about DKK 14 million as of August 28, 2026, according to MarketScreener.MarketScreener In the OTC market, the AMBFF ADR closed at 10.10 USD on the same date, down 11.40 percent for the day and showing a year-to-date performance of minus 26.28 percent, giving international investors an additional perspective on Ambu’s recent share-price trajectory.MarketScreener Taken together with the ongoing DKK 300 million buyback and the Q3 2026 results, these price levels frame Ambu stock as a medtech name where sentiment is shaped by both execution on its single-use strategy and disciplined capital allocation.